⚡ CLINICAL CANDIDACY AUDIT: October 8, 2026 • Evaluating 22.5% Clinical Trial Candidacy • Flat $129/mo Access Open
⚡ ⚡ 2026 Clinical Candidacy Evaluation

Are You an Ideal Candidate for 22.5% Clinical Weight Reduction with Tirzepatide?

Take this free 60-second clinical diagnostic to evaluate your BMI tier, glycemic history, and cardiometabolic markers, and discover whether you qualify for physician-monitored flat-rate Tirzepatide ($129/mo all doses included).

⚠️ ACCESS ALERT: CLINICAL MILESTONE ALERT: In the landmark SURMOUNT-1 clinical trial, 91% of patients taking Tirzepatide achieved at least 5% weight loss, with over 57% achieving a massive 20%+ reduction—setting the highest efficacy benchmark in medical history.
✓
Instant 60-Second Clinical Candidacy Evaluation: Evaluate your medical qualifications for dual incretin therapy.
✓
Proven Clinical Trial Efficacy: Average weight reduction of 52 lbs combined with healthy nutritional guidance.
✓
Locked Flat-Rate 503A Care: Access physician-supervised compounded Tirzepatide for just $129/mo all doses included up to 15mg.
🟢 36,810 Candidacy Audits Completed This Month • $0 Intake Fee
⚡ Question 1 of 10
10% Complete

What is your approximate Body Mass Index (BMI) or current weight profile?

Audits standard clinical qualification criteria: